查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1858039

药物动力学服务市场：按类型、按服务类型、按最终用户划分 - 全球预测 2025-2032

Pharmacokinetics Services Market by Type, Service Type, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，药物动力学服务市场规模将达到 24.3 亿美元，复合年增长率为 9.26%。

关键市场统计数据
基准年 2024 11.9亿美元
预计年份：2025年 13亿美元
预测年份 2032 24.3亿美元
复合年增长率 (%) 9.26%

本文概述了药物动力学服务在现代药物研发中的方法论基础和战略重要性。

药物动力学服务是现代药物发现和开发的重要支柱，它提供了连接分子特性与临床结果的定量基础。本导言将药物动力学定义为一个交叉学科领域，它整合了分析化学、生物分析、建模和体内实验，以表征药物的吸收、分布、代谢和排泄过程。透过描述潜在治疗药物在生物系统中的行为，药物动力学指南从临床前到临床阶段的给药策略、安全性评估和转化决策。

随着监管要求的提高和治疗方法的多样化，药物动力学实验室不断扩展其能力，以支持传统的小分子药物和日益复杂的生技药品。先进质谱技术、高通量生物分析工作流程以及基于生理的药物动力学模型的融合，显着提高了暴露-反应表征的准确性。因此，从第一线科学家到专案负责人，组织中的相关人员都依赖及时且可重复的药物动力学数据来降低专案风险、优化调查方法设计并为监管沟通提供资讯。本节将重点介绍该领域的方法论基础、跨职能重要性以及营运压力，为后续的详细分析奠定基础。

技术发展、治疗方式多样化以及监管预期正在再形成医疗服务提供者的能力和科学合作。

在技​​术进步、治疗模式组合转变和监管预期变化的推动下，药物动力学服务格局正在改变。生物分析仪器的创新，例如质谱灵敏度的提高和自动化样品处理，正在缩短週转时间并扩大可可靠定量分析的化合物范围。同时，生技药品、基因疗法药物和核酸疗法的兴起，迫使服务供应商开发与标准小分子工作流程显着不同的专用检测和基质处理能力。

此外，建模和模拟技术已发展成熟，成为重要的策略决策支援工具。基于生理学和群体药物动力学的模型现已被常规用于根据临床前数据预测人体药物动力学，选择初始人体剂量，并模拟不同的给药方案。同时，监管机构也越来越期望获得整合的药物动力学/药效学分析和透明的建模报告，促使供应商将监管文件纳入其交付成果中。这些转变正在重塑供应商与客户之间的关係，强调更深入的科学合作以及能够适应不同治疗模式和更短研发週期的灵活模组化服务。

2025年的关税调整将给供应链带来压力，并造成跨境贸易的复杂性，因此营运韧性和筹资策略至关重要。

2025年美国关税政策和贸易动态的变化将对药物动力学服务生态系统产生多方面的影响。许多服务提供者依赖进口原料、专用试剂和高价值仪器零件。这些投入品关税负担的增加可能会增加采购的复杂性，并促使企业重新评估筹资策略。为因应此挑战，各机构可以增加库存储备、筛选合格的替代供应商，或加入区域采购网络，以维持营运的连续性。

除了直接投入成本外，关税引发的贸易摩擦还会影响跨境合作在设备维护、备件供应和样品转移等方面的进度。跨境营运的合约研究机构和分析实验室可能面临额外的海关文件和潜在的延误，从而影响研究进度和客户关係。重要的是，这些动态促使人们更加关注近岸外包和供应商多元化，将其作为应对策略。因此，策略采购、合约灵活性和物流已成为相关人员的优先事项，他们希望在维持药物动力学分析所需科学严谨性的同时，减轻关税相关干扰带来的营运影响。

基于详细细分的洞察揭示了不同产品类型、服务方式和客户群的不同分析需求和交付模式。

细分市场分析揭示了跨产品类型、服务方式和最终用户类别的服务开发和客户参与路径清晰可见。依产品类型划分，市场分为大分子药物动力学服务和小分子药物动力学服务。大分子需要开发免疫测量、配体结合分析以及专门的样品处理技术来解决稳定性和基质效应问题，而小分子通常采用高解析度质谱和检验的层析法方法。按服务类型划分，市场分为体外和体内两部分，显示体外ADME和稳定性分析能够补充体内药物动力学研究，为早期候选化合物的选择和清除途径的机制理解提供资讯。按最终用户划分，市场涵盖学术和政府研究机构、生物技术公司、委外研发机构和製药公司，表明客户需求各不相同，从探索性的假设驱动研究到完全符合GLP规范且需提供完整监管申报文件的规范化研究，不一而足。

综上所述，这些细分市场决定了服务提供者必须提供模组化服务方案，用于生技药品的高灵敏度分析、小分子高通量平台以及针对最终用户的特定交付成果。学术和政府研究机构通常优先考虑方法的灵活性和新型检测方法的开发，而生物技术公司则需要敏捷性和科学伙伴关係，委外研发机构优先考虑可扩展的营运和合规性，大型製药企业则需要整合的专案管理和符合监管要求的彙报。这种主导的观点凸显了可自订的工作流程、强大的品质系统和适应性强的商业模式对于有效服务多元化客户群的重要性。

区域竞争优势和营运考量决定了药物动力学服务供应商在全球的投资、合作和规模扩张方向。

区域动态正在塑造美洲、欧洲、中东和非洲以及亚太地区的服务产品、基础设施投资和合作网络，每个地区都拥有独特的竞争优势和营运考量。在美洲，生技中心和临床开发中心的高度集中支持了快速的转化工作流程和紧密的医病关係，而监管趋势和支付方环境则影响着北美申办者对临床药理学和资料包装的重视程度。在欧洲、中东和非洲，监管体系的多元化和强大的学术研究合作促进了跨境合作、多中心研究和统一的检测验证，以满足不同司法管辖区的要求。

在亚太地区，分析能力正不断提升，这主要得益于实验室基础设施的投资以及合约研究能力的日益增长。这种成长有助于以经济高效的方式执行日益复杂的大量生物分析和生技药品业务。不同地区的物流、样本转移法规和本地人才库各不相同，这些都会影响研究设计和外包决策。因此，有效的区域策略应结合客户接近性、法规专业知识和供应链韧性，以提供一致、高品质的药物动力学服务，同时支援全球专案执行和知识转移。

竞争动态有利于那些整合了先进分析技术、跨产业专业知识和以客户为中心的商业模式，并能建立长期伙伴关係关係的供应商。

主要企业正在从单纯的交易型检测服务转型为提供涵盖生物分析、建模和法规支援的综合性科学伙伴关係。成功的公司透过投资平台自动化、数据完整性系统以及跨职能团队来脱颖而出，这些团队能够将分析结果转化为可操作的药物动力学和动态解读。与仪器製造商和软体供应商建立策略联盟可以提高分析灵敏度和通量，而内部开发的标准化报告范本则可以加快法规申报流程并促进客户决策。

此外，各公司正投资培养分析化学家、临床药理学家和建模专家等人才，以提供端到端的专案支援。在商业性，弹性价格设定模式、捆绑式配套服务以及产能保障等措施，旨在满足客户的风险承受能力和研发时间表。能够展现出持续高品质、透明的审核准备以及从早期发现到规范临床试验的扩展能力的供应商，最有可能与客户建立长期伙伴关係。总之，竞争格局青睐那些兼具深厚科学实力、卓越营运和以客户为中心的服务理念的机构。

服务供应商加强科学研究能力、营运韧性和以客户为中心的商业性框架的实际策略重点

产业领导者应优先考虑切实可行的变革，以增强科学研究能力、商业性韧性和客户契合度。首先，投资于平台自动化和稳健的生物分析工作流程可以加快週转时间并提高可重复性。其次，拓展服务团队的建模和模拟专业知识，可以帮助供应商提供预测性见解，进而指导剂量选择和研究设计，为客户专案增添策略价值。

第三，供应链多元化以及对多家试剂和设备供应商进行资格认证，可以降低贸易中断和关税相关影响带来的风险。第四，制定灵活的合约架构和基于价值的定价机制，有助于使奖励与客户保持一致，尤其对于需要定期调整专案的生技公司和赞助模式更是如此。最后，加强监管支援服务，例如文件准备和清晰的建模报告，有助于客户满足多司法管辖区的申报要求。这些倡议共同提升了营运韧性，深化了科学合作，并将供应商定位为日益复杂的药物研发路径中不可或缺的合作伙伴。

采用透明的多方法调查方法，结合专家访谈、文献综合和情境分析，检验药物动力学服务的趋势和影响。

本分析的调查方法融合了定性专家访谈、主题文献综述以及对技术和监管趋势的结构化评估。主要见解来自与药物动力学科学家、临床药理学家、实验室营运负责人和采购专家的对话，以确保对能力和限制因素有多方面的了解。次要研究包括同行评审出版物、监管指导文件和近期技术白皮书，以了解生物分析设备开发、建模方法和检测验证实践的最新进展。

分析综合强调对不同资讯来源的主题进行交叉检验，以识别一致的模式，而非孤立的观察结果。在适用情况下，透过情境分析评估营运影响，以评估供应链敏感性和不断变化的监管预期带来的影响。在整个过程中，我们始终专注于确保方法论的透明度，记录假设，并确定哪些领域需要进一步的实证研究，以利于专业的专案规划和采购决策。

总结了供应商在药物动力学服务中整合战略要务，以协调科学创新、营运韧性和以客户为中心的服务交付。

总之，药物动力学服务在将分子发现转化为安全有效的临床策略方面发挥核心作用，该领域正在适应技术、模式和地缘政治方面的压力。投资先进生物分析平台、扩展建模和模拟能力并建立稳健供应链的供应商将更有能力满足学术赞助商、生物技术公司、委外研发机构和大型製药公司的多样化需求。此外，区域动态和关税相关因素凸显了灵活采购和近岸外包策略对于确保专案进度和资料品质的重要性。

展望未来，预测模型分析结果、监管导向文件和以客户为中心的合约的紧密整合，很可能成为服务提供者差异化的关键所在。透过落实上述切实可行的建议，相关人员可以降低研发风险，加速转换里程碑的达成，并使服务交付与策略专案目标保持一致。科学、营运和商业性部门之间的持续协作，对于维护药物动力学服务生态系统的创新性和信誉至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧模型整合到早期药物动力学建模中，以优化剂量选择和预测人体药物动力学
  • 利用加速器质谱技术进行微剂量临床试验以提高安全性和生物有效性分析的需求日益增长
  • 拓展客製化体外人类肝微粒体检测服务，以支持精准医疗和药物交互作用研究
  • 利用晶片器官和微生理系统进行生理相关的药物动力学和毒性评估
  • 扩大群体药物动力学建模软体平台在癌症药物研发的应用，以简化给药方案设计
  • 将整合的PK/PD成像和生物标记分析外包给CRO，以加速先导药物最适化决策支援。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按类型分類的药物动力学服务市场

  • 大分子药物动力学服务
  • 小分子药物动力学服务

9. 按服务类型分類的药物动力学服务市场

  • 体外
  • 体内

第十章：依最终用户分類的药物动力学服务市场

  • 学术和政府研究机构
  • 生技公司
  • 受託研究机构
  • 製药公司

第十一章：按地区分類的药物动力学服务市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章：按组别分類的药物动力学服务市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：各国药物动力学服务市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Absorption Systems LLC
    • Allucent
    • Aurigene Pharmaceutical Services Ltd.
    • Certara
    • Charles River Laboratories, Inc.
    • Creative Bioarray
    • Eurofins Scientific SE
    • Evotec SE
    • Frontage Laboratories, Inc.
    • ICON PLC
    • Laboratory Corporation of America Holdings
    • LGC Limited by Cinven
    • NUVISAN Pharma Holding GmbH
    • Pacific BioLabs
    • Parexel International（MA）Corporation
    • Pfizer Inc.
    • PPD Inc. by Thermo Fisher Scientific Inc.
    • Premier Consulting
    • Reaction Biology Corporation
    • SGS SA
    • Svar Life Science AB
    • WuXi AppTec Co., Ltd.
    • XenoTech by BioIVT
    • Xyzagen
Product Code: MRR-C002B1C99681

The Pharmacokinetics Services Market is projected to grow by USD 2.43 billion at a CAGR of 9.26% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.19 billion
Estimated Year [2025] USD 1.30 billion
Forecast Year [2032] USD 2.43 billion
CAGR (%) 9.26%

Foundational overview describing the methodological backbone and strategic importance of pharmacokinetics services across modern drug development

Pharmacokinetics services are an integral pillar of contemporary drug discovery and development, providing the quantitative backbone that links molecular properties to clinical outcomes. This introduction frames pharmacokinetics as a multidisciplinary discipline that synthesizes analytical chemistry, bioanalysis, modeling, and in vivo experimentation to characterize absorption, distribution, metabolism, and excretion profiles. By establishing how therapeutic candidates behave in biological systems, pharmacokinetics guides dosing strategies, safety assessments, and translational decision-making across preclinical and clinical stages.

As regulatory expectations rise and therapeutic modalities diversify, pharmacokinetics laboratories have expanded capabilities to support both traditional small molecules and increasingly complex biologics. The convergence of advanced mass spectrometry, high-throughput bioanalytical workflows, and physiologically based pharmacokinetic modeling has improved the precision of exposure-response characterization. Consequently, organizational stakeholders-from bench scientists to program leads-depend on timely, reproducible pharmacokinetic data to de-risk portfolios, optimize trial design, and inform regulatory interactions. This section sets the stage for the deeper analyses that follow by highlighting the methodological foundations, cross-functional importance, and operational pressures shaping services in this sector.

Evolving technology, modality diversity, and regulatory expectations reshaping provider capabilities and collaborative scientific engagement

The pharmacokinetics services landscape is undergoing transformative shifts driven by technological advances, changing modality mixes, and evolving regulatory expectations. Innovations in bioanalytical instrumentation, including increased sensitivity in mass spectrometry and automation of sample processing, are shortening turnaround times and expanding the range of compounds that can be robustly quantified. At the same time, the rise of biologics, gene therapies, and nucleic acid medicines has compelled service providers to develop specialized assays and matrix handling capabilities that differ markedly from standard small molecule workflows.

Moreover, modeling and simulation techniques have matured into strategic decision-support tools. Physiologically based and population pharmacokinetic models are now routinely used to predict human pharmacokinetics from preclinical data, guide first-in-human dose selection, and simulate alternative dosing regimens. In parallel, regulatory agencies increasingly expect integrated PK/PD analyses and transparent modeling reports, prompting providers to embed regulatory-ready documentation into their deliverables. Together, these shifts are reshaping provider-client relationships, prompting deeper scientific collaboration and a focus on flexible, modular service offerings that can accommodate diverse therapeutic modalities and accelerated development timelines.

Operational resilience and procurement strategies becoming critical as tariff changes in 2025 introduce supply chain pressure and cross-border complexities

Changes to tariff policies and trade dynamics in the United States during 2025 have exerted a multifaceted influence on the pharmacokinetics services ecosystem, primarily through supply chain and cost-channel effects rather than direct scientific impact. Many service providers rely on imported raw materials, specialized reagents, and high-value instrumentation components; incremental tariff burdens on these inputs can elevate procurement complexity and prompt re-evaluation of sourcing strategies. In response, organizations may increase inventory buffers, qualify alternative suppliers, or shift to regional procurement networks to preserve operational continuity.

Beyond direct input costs, tariff-driven trade frictions can affect timelines for equipment maintenance, the availability of spare parts, and cross-border collaboration on sample transfers. Contract research organizations and analytical laboratories that operate transnationally may face additional customs documentation and potential delays, which in turn influence study timelines and client relationships. Importantly, these dynamics encourage greater attention to nearshoring and supplier diversification as resilience strategies. As a result, strategic procurement, contractual flexibility, and enhanced logistics planning have become priorities for stakeholders aiming to mitigate the operational consequences of tariff-related disruptions while maintaining the scientific rigor required for pharmacokinetic analyses.

Detailed segmentation-driven insights revealing distinct analytical requirements and delivery models across product types, service approaches, and client profiles

Segmentation analysis reveals distinct pathways for service development and client engagement across product types, service modalities, and end-user categories. Based on Type, market is studied across Large Molecules Pharmacokinetics Services and Small Molecules Pharmacokinetics Services, which highlights divergent analytical demands: large molecules require immunoassay development, ligand-binding assays, and specialized sample handling to address stability and matrix effects, whereas small molecules often leverage high-resolution mass spectrometry and validated chromatographic methods. Based on Service Type, market is studied across In-Vitro and In-Vivo, illustrating that in vitro ADME and stability assays complement in vivo pharmacokinetic studies by informing early candidate selection and mechanistic understanding of clearance pathways. Based on End-User, market is studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies, demonstrating that client needs vary from exploratory, hypothesis-driven investigations to fully regulated GLP-compliant studies with comprehensive documentation for regulatory submissions.

Taken together, these segmentation dimensions emphasize that providers must offer modular service stacks that accommodate high-sensitivity analytics for biologics, throughput-focused platforms for small molecules, and end-user-specific deliverables. Academic and government research institutes often prioritize methodological flexibility and novel assay development, biotechnology companies require agility and scientific partnership, contract research organizations focus on scalable operations and compliance, and large pharmaceutical companies demand integrated program management and regulatory-grade reporting. This segmentation-driven perspective underscores the necessity for customizable workflows, robust quality systems, and adaptable commercial models to serve a heterogeneous client base effectively.

Regional competitive advantages and operational considerations determining where pharmacokinetics service providers invest, collaborate, and scale globally

Regional dynamics shape service provision, infrastructure investment, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each offering unique competitive advantages and operational considerations. In the Americas, dense concentrations of biotechnology hubs and clinical development centers support rapid translational workflows and close provider-client interactions, while regulatory pathways and payer environments influence the emphasis on clinical pharmacology and data packages for North American sponsors. In Europe, Middle East & Africa, the regulatory mosaic and strong academic-research linkages encourage cross-border collaborations, multi-center studies, and harmonized assay validation to meet diverse jurisdictional expectations.

The Asia-Pacific region has expanded analytical capacity, driven by investment in laboratory infrastructure and a growing base of contract research capability; this growth supports cost-effective execution of high-volume bioanalysis and increasingly sophisticated work in biologics. Across regions, logistical considerations, sample transfer regulations, and local talent pools inform decisions about study design and outsourcing. Therefore, effective regional strategies blend proximity to clients, regulatory expertise, and supply chain resilience to deliver consistent, high-quality pharmacokinetic services while enabling global program execution and knowledge transfer.

Competitive dynamics favor providers that integrate advanced analytics, cross-disciplinary expertise, and client-centric commercial models to drive long-term partnerships

Leading companies in the pharmacokinetics services arena are evolving beyond transactional assay delivery to provide integrated scientific partnerships that span bioanalysis, modeling, and regulatory support. Successful firms differentiate through investments in platform automation, data integrity systems, and cross-functional teams that translate analytical output into actionable pharmacokinetic and pharmacodynamic interpretations. Strategic collaborations with instrument manufacturers and software vendors enhance analytical sensitivity and throughput, while internal development of standardized reporting templates accelerates regulatory submissions and client decision-making.

Moreover, companies are investing in talent development-combining analytical chemists, clinical pharmacologists, and modelers-to offer end-to-end program support. Commercially, flexible pricing models, bundled service offerings, and capacity guarantees are being used to align with client risk profiles and development timelines. Providers that demonstrate consistent quality, transparent audit readiness, and the ability to scale from early discovery to regulated clinical studies are most likely to retain long-term partnerships. In sum, the competitive landscape rewards organizations that pair scientific depth with operational excellence and client-centric service design.

Practical strategic priorities for service providers to strengthen scientific capabilities, operational resilience, and client-aligned commercial frameworks

Industry leaders should prioritize actionable changes that strengthen scientific capability, commercial resilience, and client alignment in the near term. First, investing in platform automation and robust bioanalytical workflows can reduce turnaround times and improve reproducibility, which is essential for maintaining competitiveness as therapeutic modalities diversify. Second, expanding modeling and simulation expertise within service teams enables providers to offer predictive insights that inform dose selection and trial design, thereby adding strategic value to client programs.

Third, diversifying supply chains and qualifying multiple reagent and equipment vendors mitigates risks from trade disruptions and tariff-related impacts. Fourth, developing flexible contracting frameworks and value-based pricing can align incentives with clients, particularly for biotechnology companies and sponsorship models that require iterative program adjustments. Finally, enhancing regulatory support services-including documentation readiness and clear modeling reports-helps clients navigate multi-jurisdictional submission requirements. Collectively, these initiatives will improve operational resilience, deepen scientific engagement, and position providers as indispensable partners in increasingly complex drug development pathways.

Transparent multi-method research approach combining expert interviews, literature synthesis, and scenario analysis to validate pharmacokinetics service trends and implications

The research methodology underpinning this analysis integrates qualitative expert interviews, subject-matter literature review, and a structured assessment of technological and regulatory trends. Primary insights were derived from conversations with pharmacokinetic scientists, clinical pharmacologists, laboratory operations leaders, and procurement specialists, ensuring a multi-perspective understanding of capabilities and constraints. Secondary research included peer-reviewed publications, regulatory guidance documents, and recent technical white papers to capture advancements in bioanalytical instrumentation, modeling approaches, and assay validation practices.

Analytical synthesis emphasized cross-validation of themes across sources to identify consistent patterns rather than isolated observations. Where applicable, operational impacts were evaluated through scenario analysis to assess supply chain sensitivity and the implications of evolving regulatory expectations. Throughout, careful attention was paid to ensuring methodological transparency, documenting assumptions, and identifying areas where further empirical investigation would be valuable for specialized program planning or procurement decisions.

Concluding synthesis of strategic imperatives for providers to align scientific innovation, operational resilience, and client-focused delivery in pharmacokinetics services

In conclusion, pharmacokinetics services occupy a central role in translating molecular discovery into safe and efficacious clinical strategies, and the sector is adapting to technological, modality, and geopolitical pressures. Providers that invest in advanced bioanalytical platforms, expand modeling and simulation capabilities, and build resilient supply chains will be best positioned to meet the diverse needs of academic sponsors, biotechnology firms, contract research organizations, and large pharmaceutical companies. Furthermore, regional dynamics and tariff-related considerations underscore the importance of flexible sourcing and nearshoring strategies to preserve timelines and data quality.

Looking ahead, closer integration of analytical output with predictive modeling, regulatory-focused documentation, and client-centric contracting will define provider differentiation. By pursuing the actionable recommendations outlined earlier, stakeholders can reduce development risk, accelerate translational milestones, and align service delivery with strategic program objectives. Continued collaboration across scientific, operational, and commercial functions will be essential to sustain innovation and reliability within the pharmacokinetics services ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence models in early-phase pharmacokinetics modeling to optimize dose selection and predict human pharmacokinetics
  • 5.2. Rising demand for microdosing clinical trials using Accelerator Mass Spectrometry for enhanced safety and bioavailability profiling
  • 5.3. Expansion of custom in vitro human liver microsome testing services to support precision medicine and drug-drug interaction studies
  • 5.4. Adoption of organ-on-chip and microphysiological systems for physiologically relevant pharmacokinetics and toxicity assessments
  • 5.5. Growing utilization of population pharmacokinetic modeling software platforms in oncology drug development to streamline dose regimen design
  • 5.6. Shift toward outsourcing integrated PK/PD imaging and biomarker analytics to CROs for accelerated decision support in lead optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pharmacokinetics Services Market, by Type

  • 8.1. Large Molecules Pharmacokinetics Services
  • 8.2. Small Molecules Pharmacokinetics Services

9. Pharmacokinetics Services Market, by Service Type

  • 9.1. In-Vitro
  • 9.2. In-Vivo

10. Pharmacokinetics Services Market, by End-User

  • 10.1. Academic & Government Research Institutes
  • 10.2. Biotechnology Companies
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical Companies

11. Pharmacokinetics Services Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Pharmacokinetics Services Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Pharmacokinetics Services Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Absorption Systems LLC
    • 14.3.2. Allucent
    • 14.3.3. Aurigene Pharmaceutical Services Ltd.
    • 14.3.4. Certara
    • 14.3.5. Charles River Laboratories, Inc.
    • 14.3.6. Creative Bioarray
    • 14.3.7. Eurofins Scientific SE
    • 14.3.8. Evotec SE
    • 14.3.9. Frontage Laboratories, Inc.
    • 14.3.10. ICON PLC
    • 14.3.11. Laboratory Corporation of America Holdings
    • 14.3.12. LGC Limited by Cinven
    • 14.3.13. NUVISAN Pharma Holding GmbH
    • 14.3.14. Pacific BioLabs
    • 14.3.15. Parexel International (MA) Corporation
    • 14.3.16. Pfizer Inc.
    • 14.3.17. PPD Inc. by Thermo Fisher Scientific Inc.
    • 14.3.18. Premier Consulting
    • 14.3.19. Reaction Biology Corporation
    • 14.3.20. SGS SA
    • 14.3.21. Svar Life Science AB
    • 14.3.22. WuXi AppTec Co., Ltd.
    • 14.3.23. XenoTech by BioIVT
    • 14.3.24. Xyzagen

LIST OF FIGURES

  • FIGURE 1. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PHARMACOKINETICS SERVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY LARGE MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SMALL MOLECULES PHARMACOKINETICS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 63. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 65. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 67. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 74. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 76. NORTH AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 80. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 84. LATIN AMERICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 93. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 97. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 104. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. MIDDLE EAST PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 109. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 116. AFRICA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 130. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 131. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 134. ASEAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 135. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GCC PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 151. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 158. BRICS PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 159. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 166. G7 PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 167. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. NATO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PHARMACOKINETICS SERVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 183. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 207. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. GERMANY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. FRANCE PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 219. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. RUSSIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. ITALY PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 236. SPAIN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 237. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. CHINA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 243. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. INDIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 254. JAPAN PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 260. AUSTRALIA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY SERVICE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. SOUTH KOREA PHARMACOKINETICS SERVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 267. PHARMACOKINETICS SERVICES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 268. PHARMACOKINETICS SERVICES MARKET, FPNV POSITIONING MATRIX, 2024